Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 10Phase NA 9Phase 1/2 8Phase 3 3Phase 4 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Lymphoid 4Other neoplasm 3Myeloid 3Classical hematology 2Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Trimethoprim, Sulfamethoxazole Drug Combination 4Thalidomide 4Cyclophosphamide 4gamma-Globulins 3Ciprofloxacin 3carfilzomib 2Melphalan 2Immunoglobulins, Intravenous 2Calcium Dobesilate 2Amoxicillin-Potassium Clavulanate Combination 2trametinib 1tanespimycin 1pomalidomide 1pazopanib 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Radiotherapy 1Radiation 1Pharmaceutical Preparations 1Mesna 1MAGEA3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Busulfan × Plasma cell × Clear all
NCT03385096 2020-02-25

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
122 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡